ST. LOUIS, Feb. 13, 2013 /PRNewswire/ -- Sigma-Aldrich ® Corporation (NASDAQ: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, through an exclusive collaboration with Drs. Hideo Iba and Takeshi Haraguchi at the University of Tokyo, released MISSION ® Synthetic and Lentiviral microRNA Inhibitors based upon the Tough Decoy (TuD) design for the long-term suppression of any miRNA endogenous to humans or mice. Custom designs for other species are available upon request. Each microRNA inhibitor is designed using a proprietary algorithm that evaluates all possible sequences for the design predicted to best maintain the TuD structure, providing maximal miRNA recognition and binding . For more information, visit www.sigma.com/inhibitors.
Naturally-occurring miRNAs inhibit translation of a large percentage of mRNAs encoding human proteins and play pivotal roles in oncogenesis, development, cell differentiation, and immune responses. Iba and Haraguchi invented TuD RNAs 1,2 as a more potent tool to suppress specific miRNAs and thus investigate their biological functions.
In contrast to current approaches that use single-stranded RNAs, such as sponge decoys and locked nucleic acids, TuD RNAs are double-stranded. This, along with a stem-loop stabilized secondary structure, resists cellular nuclease degradation and facilitates sustained miRNA inhibition for longer than one month. In addition, both strands of a TuD RNA contain an miRNA binding site for more efficient sequestration of target miRNAs at lower, nanomolar concentrations.
"Drs. Iba and Haraguchi's Tough Decoy RNAs are an elegant and more practical tool for exploring the impact of microRNA gene regulation on human disease. Sigma Life Science's mission is to support this field's rapid development by making keystone technologies like this broadly accessible," says Dr. Supriya Shivakumar, Director of Emerging Technologies at Sigma Life Science.Sigma Life Science provides the TuD RNAs in both synthetic and lentiviral formats to support transient miRNA knockdown as well as long-term miRNA suppression without repeated transfections. The miRNA binding sites are designed using human and mouse sequence data from the most recent version of miRBase (v.19).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV